Clinical Trials
50 trialsA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI)
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
PNeoVCA
Mayo Clinic
Tebentafusp-tebn With LDT in Metastatic UM
Thomas Jefferson University
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Ultimovacs ASA
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Ultimovacs ASA
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
National Cancer Institute (NCI)
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Sargramostim (GM-CSF) + PD-1
Dana-Farber Cancer Institute
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
Roswell Park Cancer Institute
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Jonsson Comprehensive Cancer Center
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
National Cancer Institute (NCI)
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
University of Virginia
GIPI
Northern California Melanoma Center
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Mayo Clinic
Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma
University of Wisconsin, Madison
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
University of Texas Southwestern Medical Center
Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma
Mayo Clinic
REO13 Melanoma With of Without GM-CSF
University of Leeds
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
University of California, Irvine
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
University of Pittsburgh
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
UNC Lineberger Comprehensive Cancer Center
DCVaccineMel
Hoag Memorial Hospital Presbyterian
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Alliance for Clinical Trials in Oncology
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
BioVex Limited
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Alliance for Clinical Trials in Oncology
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
National Cancer Institute (NCI)
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
University of Virginia
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
University of Virginia
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
University of Virginia
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
University of Virginia
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
University of Southern California
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
University of Southern California
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
University of Southern California
Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma
National Cancer Institute (NCI)
Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
University of Virginia
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
Memorial Sloan Kettering Cancer Center
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
University of Alabama at Birmingham
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
Dartmouth-Hitchcock Medical Center
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
National Cancer Institute (NCI)
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma
National Cancer Institute (NCI)
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
Memorial Sloan Kettering Cancer Center
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
Scripps Health